System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Alessandro Armuzzi is an expert in Gastroenterology at IRCCS Humanitas Research Hospital (Italy). As of October 2026, ScienceLeadR ranks Alessandro Armuzzi in the top 1% of experts worldwide for Colitis, Gastroenteritis and Inflammatory Bowel Diseases. Alessandro Armuzzi has authored 929 publications, the most recent in 2026, and is an investigator in 75 clinical trials, 38 of them ongoing. SLR score: 4,742 (community average: 125). How the SLR is computed.

LeadR Profile

Alessandro Armuzzi IRCCS Humanitas Research Hospital Italy
4 742 ScienceLeadR Reputation 4742

Unlock

Register Login
Network Map

Gastroenterology

Subspecialties: Pharmacy - Hepatology - Public Health

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2000 - 2026
Source: PubMed

Agostino Gemelli University Polyclinic

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 929

Citations

Citations: 23 960 1st author: 81 Last author: 203 Unique author: 0

Main journals

J Crohns Colitis 197
Dig Liver Dis 177
Gastroenterology 114
Inflamm Bowel Dis 37
Am J Gastroenterol 32

Best Journals

Gastroenterology 6
Lancet Gastroenterol Hepatol 5
N Engl J Med 5

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Mirikizumab is associated with improvements in bowel urgency and quality of life in moderately-to-severely active ulcerative colitis: 28-week phase 3b results from the LUCENT-URGE trial.
PMID 42927097 — quality of life, colitis, signs and symptoms, colitis, ulcerative		Crohns Colitis 36020260
Beyond 'early surgery': Reframing Ileocaecal resection as strategic care in Crohn's disease.
PMID 42886632 — crohn disease, therapeutics		Colorectal Dis20260
Phase 2 Trial of Icotrokinra for Patients with Ulcerative Colitis.
PMID 42874103 — research design, interleukin-23, colitis, respect, drug-related side effects and adverse reactions, colitis, ulcerative		N Engl J Med Top journal20260
Real-World Epidemiology of Inflammatory Bowel Disease in Italy: Treatment Patterns, Adherence, and Costs in Patients with Ulcerative Colitis Treated with Mesalazine.
PMID 42862468 — financial stress, health care costs, epidemiology, colitis, mesalamine, inflammatory bowel diseases, therapeutics, colitis, ulcerative		Drugs Real World Outcomes20260
Clinical Characteristics of Patients Presenting with Moderate-to-Severe Atopic Dermatitis and Concomitant Inflammatory Bowel Diseases: a Multicenter Retrospective Study.
PMID 42858396 — dermatitis, retrospective studies, inflammatory bowel diseases, prevalence, diagnosis, dermatitis, atopic		Dermatol Pract Concept20260

Clinical Studies 75

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 11

By phase:

Phase 2 32
Phase 3 29
N/A 8
Phase 2/Phase 3 3
Phase 4 3

By status:

Recruiting 26
Completed 23
Not yet recruiting 9
Terminated 8
Unknown 5
Active not recruiting 4

By type:

Interventional 70
Observational 5

By Monocentric/Multicentric:

monocentric 8
multicentric2to4 1
multicentric5to9 0
multicentricup10 66

Main Topics

Cohort/Consortium Investigators 4

Ongoing Clinical Trials

38 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Efficacy and Safety of JNJ 78934804 in Participants With Moderately to Severely Active Crohn s Disease
2026-525922-39-00 — safety, crohn disease		Phase 3Not yet recruiting2026
Efficacy and Safety of JNJ 78934804 in Participants with Moderately to Severely Active Ulcerative Colitis
2026-525923-26-00 — colitis, safety, colitis, ulcerative		Phase 3Recruiting2026
A Study to Assess the Efficacy Safety and what the body does to RO7837195 in Participants with Moderately to Severely Active Ulcerative Colitis
2025-520690-39-00 — colitis, safety, therapeutics, colitis, ulcerative, pharmacokinetics		Phase 2Not yet recruiting2025
A Phase 2 Platform Study to Evaluate Therapies for Inflammatory Bowel Disease
2025-522001-38-00 — colitis, safety, crohn disease, multiple chronic conditions, inflammatory bowel diseases, therapeutics, colitis, ulcerative, pharmacokinetics		Phase 2Recruiting2026
A study to investigate the long term safety tolerability and efficacy of balinatunfib in participants with Crohn s disease or ulcerative colitis
2025-522511-42-00 — colitis, safety, crohn disease, colitis, ulcerative		Phase 2Recruiting2026

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS